Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Trends in Cancer|May 2, 2022
Utilizing chemokines in cancer immunotherapyFlorian Märkl, Duc Huynh, Stefan Endres, et al.Seminars in Immunopathology|September 27, 2022
Beyond direct killing-novel cellular immunotherapeutic strategies to reshape the tumor microenvironmentDuc Huynh, Pia Winter, Florian Märkl, et al.Cancer Immunology, Immunotherapy : CII|April 11, 2023
CD33 BiTE<sup>®</sup> molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cellsAnetta Marcinek, Bettina Brauchle, Lisa Rohrbacher, et al.Cancer Immunology, Immunotherapy : CII|April 17, 2024
Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myelomaSophia Stock, Luisa Fertig, Adrian Gottschlich, et al.British Journal of Cancer|July 3, 2023
Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapyTheo Lorenzini, Bruno L Cadilha, Hannah Obeck, et al.British Journal of Cancer|October 20, 2022
Impact of the selective A2<sub>A</sub>R and A2<sub>B</sub>R dual antagonist AB928/etrumadenant on CAR T cell functionMatthias Seifert, Mohamed-Reda Benmebarek, Daria Briukhovetska, et al.Blood Advances|February 24, 2026
FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustionLisa Rohrbacher, Daniel Nixdorf, Helena Stadler, et al.Blood Advances|December 1, 2025
FLT3-directed BiTE Molecules versus CAR T Cells in AML: Co-stimulatory Signals Mitigate T-Cell ExhaustionLisa Rohrbacher, Daniel Nixdorf, Helena Stadler, et al.Nature Communications|February 2, 2024
Mutation-specific CAR T cells as precision therapy for IGLV3-21<sup>R110</sup> expressing high-risk chronic lymphocytic leukemiaFlorian Märkl, Christoph Schultheiß, Murtaza Ali, et al.Journal for Immunotherapy of Cancer|May 19, 2023
Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanomaFlorian Märkl, Mohamed-Reda Benmebarek, Julius Keyl, et al.Pageof 2